Panacea Acquisition Corp. II
PANA
NASDAQ Capital Market10.24
USD
-0.01
- -
CIK
0001828989
ISIN
KYG6882C1069
CUSIP
G6882C106
Return %
Stock
S&P500
1Y
5.24
26.84
3Y
2.40
77.03
5Y
2.40
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Oleg Nodelman
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 357 Tehama Street San Francisco CA United States of America 94103
- IPO Date
- Apr 7, 2021
- CIK
- 0001828989
- Similar Companies
- Business
- Panacea Acquisition Corp. II (PANA) operates as a blank check company whose purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting companies in the biotechnology sector domiciled in North America or Europe; it currently conducts no significant operations and generates no revenues. Sponsored by EcoR1 Panacea Holdings II LLC, the company maintains funds in a trust account from its initial public offering for potential deployment in a qualifying transaction. Incorporated in 2021 and headquartered at 357 Tehama Street, Floor 3, San Francisco, California, it trades on the Nasdaq under the ticker PANA. In April 2023, Panacea Acquisition Corp. II failed to complete an initial business combination by the deadline specified in its amended charter, resulting in a decision to liquidate, redeem outstanding shares, and dissolve the company no later than April 21, 2023, with Nasdaq delisting to follow. Prior to liquidation, the company raised $172.5 million in gross proceeds through its April 2021 IPO of 15 million Class A ordinary shares priced at $10.00 each, plus private placement shares, placing substantially all net proceeds into trust; it pursued but did not finalize any merger, unlike its affiliate Panacea Acquisition Corp. which combined with Nuvation Bio Inc. in 2021. The sponsor team, led by CEO and Chairman Oleg Nodelman of EcoR1 Capital, focused on healthcare opportunities without announcing partnerships, funding rounds, new offerings, or operational expansions in the lead-up to dissolution.
Panacea Acquisition Corp. II Announces Pricing of $150,000,000 Initial Public Offering
Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio
Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio
Panacea Acquisition Corp. Announces the Separate Trading of its Shares of Class A Common Stock and Redeemable Warrants Commencing August 21, 2020
Panacea Acquisition Corp. Announces Pricing of $125,000,000 Initial Public Offering